Emerging Non-Insulin Approaches to Better Manage the Complexities of T2DM
The T2DM treatment paradigm has shifted significantly over the past few years with the emergence of new therapies designed to better address underlying pathophysiologic defects, while reducing untoward events and improving health outcomes. This rich array of emerging therapeutic options, alongside existing treatment approaches, can become overwhelming and potentially confusing as we look for the best clinical strategies to meet our patients’ needs. In this webcast, leading experts will discuss the latest evidence-based guideline recommendations for management of T2DM across the continuum of care, while lending practical insights on how to best tailor treatment based on a patient’s individual clinical presentation, risks, and needs. Discussion will focus on distinguishing new and emerging non-insulin therapies, including GLP-1 receptor agonists, in order to improve glycemic control, overcome clinical challenges, and mitigate cardiometabolic risks.
Contracted Research for Lexicon Pharmaceuticals, Inc.; Ligand Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk Inc.; Sanofi US; and Takeda Pharmaceuticals U.S.A, Inc. Speaker’s Bureau for Novo Nordisk Inc. and Takeda Pharmaceuticals U.S.A, Inc. Services Provided for Promotional Purposes (Not for CME/CE Services) for AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Eisai Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novo Nordisk Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A, Inc.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
pmiCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
pmiCME is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider number 040308. This activity was planned in accordance with AANP Accreditation Standards and Policies.
This program has been approved for 1.09 contact hours of continuing education, which includes 0.39 hour of pharmacology.
Once you have completed the activity, please click the "next" button to advance to the post-activity assessment. To complete this activity and claim credit, you must answer 3 out of the 5 questions correctly. If you are not successful after your first attempt, you will be given an opportunity to reflect upon the answer rationales and have the opportunity to review the educational content before proceeding. Once you have selected your answers, click the "submit" button to complete the evaluation questions and proceed to the claim credit screen.
Novo Nordisk Inc.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.